News

LifeCycle Pharma (LCP) has submitted the phase 3 protocol for LCP-Tacro in de novo kidney transplant recipients, to the FDA. LCP is expected to review the protocol with

Compugen has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates, for three drug targets of interest to Pfizer. Reportedly,

Synta Pharmaceuticals (Synta) has initiated phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a

Novexel has signed a definitive agreement whereby the company shall be acquired by AstraZeneca for a total cash consideration of up to $505m. The transaction is expected to

The HHS Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract to Elusys Therapeutics (Elusys) of Pine Brook, for the advanced development of a medication to

Applied NeuroSolutions has reached an agreement with Eli Lilly to increase the scope of its drug discovery collaboration. In addition to the financial terms from the original collaboration

Impax Laboratories (Impax) has initiated a challenge of the patents listed by Abbott Laboratories in connection with its Tricor (fenofibrate) tablets, 48mg and 145mg. Tricor is indicated as

Amgen has reported that the US District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen’s patents on recombinant

NicOx has submitted a marketing authorization application (MAA) for naproxcinod to the European Medicines Agency (EMEA), seeking approval for an indication for the relief of the signs and